Cargando…
Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma
SIMPLE SUMMARY: Cancer immunotherapy involves the application of strategies aimed at enhancing the body’s immune system to recognize and clear tumor cells. One such immunotherapeutic approach utilizes cytotoxic immune cells (T cells) harvested from the patient, which are expanded and activated, foll...
Autores principales: | Krabbe, Teresa, Marek, Janina, Groll, Tanja, Steiger, Katja, Schmid, Roland M., Krackhardt, Angela M., Altomonte, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958625/ https://www.ncbi.nlm.nih.gov/pubmed/33801359 http://dx.doi.org/10.3390/cancers13051044 |
Ejemplares similares
-
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy
por: Marek, Janina, et al.
Publicado: (2023) -
Fusogenic Viruses in Oncolytic Immunotherapy
por: Krabbe, Teresa, et al.
Publicado: (2018) -
Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers
por: Melzer, Michael Karl, et al.
Publicado: (2018) -
Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy
por: Reale, Alberto, et al.
Publicado: (2021) -
A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma
por: Takaoka, Hiroo, et al.
Publicado: (2011)